Tumor Biology

, Volume 34, Issue 2, pp 901–907 | Cite as

RETRACTED ARTICLE: Polymorphisms of excision repair gene XPD Lys751Gln and hOGG1 Ser326Cys might not be associated with hepatocellular carcinoma risk: a meta-analysis

  • Ri-Chu Zhang
  • Si-Hua Mou
Research Article


The xeroderma pigmentosum group D (XPD) and human 8-oxoguanine glycosylase 1 (hOGG1) genes have been suggested to play an important role in the pathogenesis of hepatocellular carcinoma (HCC). However, the results have been inconsistent. In this study, we performed a meta-analysis to clarify the associations of polymorphisms of XPD and hOGG1 genes with HCC risk. Published literature from PubMed, EMBASE, and Chinese National Knowledge Infrastructure were retrieved. Pooled odds ratio (OR) with 95 % confidence interval (CI) was calculated using a fixed- or random-effects model. Seven studies (1,955 HCC cases and 2,023 controls) for XPD Lys751Gln polymorphism and six studies (1,470 HCC cases and 1,541 controls) for hOGG1 Ser326Cys polymorphism were included in the final meta-analysis. For XPD Lys751Gln polymorphism, no significant association was found under all genetic models (Gln/Gln vs Lys/Lys OR = 1.09, 95 % CI = 0.28–4.18; Gln/Lys vs Lys/Lys OR = 1.41, 95 % CI = 0.81–2.44; dominant model OR = 1.40, 95 % CI = 0.77–2.57; recessive model OR = 1.02, 95 % CI = 0.33–3.23). For hOGG1 Ser326Cys polymorphism, there was a significant association of this polymorphism with HCC risk under heterogeneous codominant model (OR = 1.38, 95 % CI = 1.01–1.88) and dominant model (OR = 1.57, 95 % CI = 1.14–2.16). The sensitivity analysis indicated that the significant association between hOGG1 Ser326Cys polymorphism and HCC risk was not robust. The present meta-analysis has limited evidence to support the association of XPD Lys751Gln and hOGG1 Ser326Cys polymorphisms with HCC risk. Further, large-scale studies with the consideration for gene–gene/gene–environment interactions should be conducted to investigate the association.


XPD hOGG1 Polymorphism Hepatocellular carcinoma Meta-analysis 



The work was funded by the Zhejiang Medicine, Health, and Science (no. 2010KYB127), Zhejiang Province Chinese Medicine Research Program (2012ZA130), and Zhejiang Gong Yi Xing Technology Application Project (2012C33025).

Conflicts of interest



  1. 1.
    Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer. 2007;96:1127–34.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Gao J, Xie L, Yang WS, Zhang W, Gao S, Wang J, et al. Risk factors of hepatocellular carcinoma—current status and perspectives. Asian Pac J Cancer Prev. 2012;13:743–52.CrossRefPubMedGoogle Scholar
  3. 3.
    Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis. 2002;17:463–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Shen M, Hung RJ, Brennan P, Malavielle C, Donato F, Placidi D, et al. Polymorphisms of the DNA repair genes XRCC1, XRCC3, XPD, interaction with environmental exposure, and bladder cancer risk in a case–control study in Northern Italy. Cancer Epidemiol Biomark Prev. 2003;12:1234–40.Google Scholar
  5. 5.
    Xu L, Wu Y, Jin Y, Yu Y, Qian G. A case–control study on polymorphism of DNA repair gene XPD and susceptibility to hepatocellular carcinoma. Tumor. 2004;24:526–9. in Chinese.Google Scholar
  6. 6.
    Chen CC, Yang SY, Liu CJ, Lin CL, Liaw YF, Lin SM, et al. Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. Int J Epidemiol. 2005;34:1310–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Xie W. Association between the nucleotide excision repair (NER) genes polymorphisms and genetic susceptibility and clinical phenotype of hepatocellular carcinoma. Doctoral Dissertation of Guangxi Medical University 2007; 1–103. in Chinese.Google Scholar
  8. 8.
    Long XD, Ma Y, Zhou YF, Yao JG, Ban FZ, Huang YZ, et al. XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and hepatocellular carcinoma risk. BMC Cancer. 2009;9:400.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Cui X, Su H. A case–control study on the polymorphism of gene XPD and the susceptibility of primary hepatic carcinoma. Med J Chin People’s Health. 2010;22:912–4. in Chinese.Google Scholar
  10. 10.
    Gulnaz A, Sayyed AH, Amin F, Khan AU, Aslam MA, Shaikh RS, et al. Association of XRCC1, XRCC3, and XPD genetic polymorphism with an increased risk of hepatocellular carcinoma because of the hepatitis B and C virus. Eur J Gastroenterol Hepatol. 2012. doi: 10.1097/MEG.0b013e328359a775.
  11. 11.
    Hu H, Zhang C, Deng W, Huang Q, Dong X, Wang C, et al. Study on the familial aggregation factors of hepatocellular carcinoma. Yiyao Qianyan. 2012;2:143–4. in Chinese.Google Scholar
  12. 12.
    Boiteux S, Radicella JP. The human OGG1 gene: structure, functions, and its implication in the process of carcinogenesis. Arch Biochem Biophys. 2000;377:1–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Weiss JM, Goode EL, Ladiges WC, Ulrich CM. Polymorphic variation in hOGG1 and risk of cancer: a review of the functional and epidemiologic literature. Mol Carcinog. 2005;42:127–41.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhang H, Hao B, He F. Studies on association between susceptibility of hepatocellular carcinoma and genetic polymorphism Ser326Cys of DNA repair gene hOGG1. Chin J Clin Oncol. 2005;32:841–3. in Chinese.Google Scholar
  15. 15.
    Sakamoto T, Higaki Y, Hara M, Ichiba M, Horita M, Mizuta T, et al. hOGG1 Ser326Cys polymorphism and risk of hepatocellular carcinoma among Japanese. J Epidemiol. 2006;16:233–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Wang A, Cong W, He X, Jia H, Jin X, Zhu G, et al. A hOGG1 gene polymorphism and genetic susceptibility to colorectal cancer and hepatocellular carcinoma. Chin J Gastroenterol Hepatol. 2008;17:854–7. in Chinese.Google Scholar
  17. 17.
    Ji L, Zeng X, Li L, Chou X, Chen S, Yu H. Interaction between the single-nucleotide polymorphism of DNA repair gene hOGG1 and HBV infection and its susceptibility to hepatocellular carcinoma. J Hyg Res. 2011;40:705–8. in Chinese.Google Scholar
  18. 18.
    Tang G, Li X, Liu T, Yang J, Luo J, Liang Z. Genetic polymorphisms of DNA repair genes in patients with hepatocellular carcinoma. Shandong Med J. 2011;51:19–20. in Chinese.Google Scholar
  19. 19.
    Yuan T, Wei J, Luo J, Liu M, Deng S, Chen P. Polymorphisms of base-excision repair genes hOGG1 326cys and XRCC1 280His increase hepatocellular carcinoma risk. Dig Dis Sci. 2012;57:2451–7.CrossRefPubMedGoogle Scholar
  20. 20.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMedGoogle Scholar
  21. 21.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  22. 22.
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.CrossRefPubMedGoogle Scholar
  23. 23.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Yuan T, Deng S, Liu H, Liu M, Chen P. Relationship between XRCC1 and XPD polymorphisms and the risk of the development of hepatocellular carcinoma: a case–control study. Exp Ther Med. 2012;4:285–90.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Long XD, Ma Y, Zhou YF, Ma AM, Fu GH. Polymorphism in xeroderma pigmentosum complementation group C codon 939 and aflatoxin B1-related hepatocellular carcinoma in the Guangxi population. Hepatology. 2010;52:1301–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Mi Y, Zhang L, Feng N, Wu S, You X, Shao H, et al. Impact of two common xeroderma pigmentosum group D (XPD) gene polymorphisms on risk of prostate cancer. PLoS One. 2012;7:e44756.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Zhu S, Zhang H, Tang Y, Wang J. Polymorphisms in XPD and hOGG1 and prostate cancer risk: a meta-analysis. Urol Int. 2012;89:233–40.CrossRefPubMedGoogle Scholar
  28. 28.
    Xue H, Lu Y, Lin B, Chen J, Tang F, Huang G. The effect of XPD/ERCC2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis. PLoS One. 2012;7:e43431.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Li BR, Zhou GW, Bian Q, Song B. Lack of association between the hOGG1 Ser326Cys polymorphism and gastric cancer risk: a meta-analysis. Asian Pac J Cancer Prev. 2012;13:1145–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Duan XL, Gong H, Zeng XT, Ni XB, Yan Y, Chen W, et al. Association between XPD Asp312Asn polymorphism and esophageal cancer susceptibility: a meta-analysis. Asian Pac J Cancer Prev. 2012;13:3299–303.CrossRefPubMedGoogle Scholar
  31. 31.
    Yuan H, Niu YM, Wang RX, Li HZ, Chen N. Association between XPD Lys751Gln polymorphism and risk of head and neck cancer: a meta-analysis. Genet Mol Res. 2011;10:3356–64.CrossRefPubMedGoogle Scholar
  32. 32.
    Liu J, Cao XL, Zhang Z, Lei DP, Jin T, Yu XM, et al. HOGG1 Ser326Cys polymorphism and susceptibility to head and neck cancer: a meta-analysis. Asian Pac J Cancer Prev. 2011;12:2491–4.PubMedGoogle Scholar
  33. 33.
    Feng Z, Ni Y, Dong W, Shen H, Du J. Association of ERCC2/XPD polymorphisms and interaction with tobacco smoking in lung cancer susceptibility: a systemic review and meta-analysis. Mol Biol Rep. 2012;39:57–69.CrossRefPubMedGoogle Scholar
  34. 34.
    Zhong D, Li G, Long J, Wu J, Hu Y. The hOGG1Ser326Cys polymorphism and increased lung cancer susceptibility in Caucasians: an updated meta-analysis. Sci Rep. 2012;2:548.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Pabalan N, Francisco-Pabalan O, Sung L, Jarjanazi H, Ozcelik H. Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer. Breast Cancer Res Treat. 2010;124:531–41.CrossRefPubMedGoogle Scholar
  36. 36.
    Yuan W, Xu L, Feng Y, Yang Y, Chen W, Wang J, et al. The hOGG1 Ser326Cys polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010;122:835–42.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  1. 1.Department of General SurgeryTaizhou Municipal HospitalTaizhouChina
  2. 2.Department of Clinical LaboratoryTaizhou Municipal HospitalTaizhouChina

Personalised recommendations